• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Adverse Drug Reaction (ADR) of Hydroxychloroquine(HCQ) in the -Preexposure Prophylaxis (PrEP) of COVID-19 in Health Care Professionals in a Tertiary Care Teaching Hospital
  • VIEWS 581
  • PDF 188

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v22.4.72

Year: 2023, Volume: 22, Issue: 4, Pages: 206-210

Original Article

Adverse Drug Reaction (ADR) of Hydroxychloroquine(HCQ) in the -Preexposure Prophylaxis (PrEP) of COVID-19 in Health Care Professionals in a Tertiary Care Teaching Hospital

Pranav S Jadhav1,*, Saleem B Tamboli2, Rahul B Parsode3

1Assistant Professor, Dept of Pharmacology, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, India
2Professor and Head, Dept of Pharmacology, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, India
3Assistant Professor, Dept of Pharmacology, Dr Shankarrao Chavan Government Medical College, Nanded, India

*Corresponding author email: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

In December 2019 an outbreak of emerging COVID-19 due to the SARS CoV-2 infection started in Wuhan, China and rapidly spread throughout the world. WHO declared COVID-19 as PANDEMIC on 12th March 2020. Various drugs were introduced to treat and prevent this pandemic. Hydroxychloroquine gained widespread attention due to its antiviral action and inhibitory effect. HCQ was preferred which has antiviral effect similar to that of Chloroquine. ICMR and FDA has advocated their use in severe COVID-19 disease. There are uncertain and limited data to support the beneficial effect of this drug. Our study was aimed to investigate the adverse drug reaction of HCQ given prophylactically for COVID-19 to the health care professional. After taking ethical committee approval, a study was conducted among the health care professional from 1st April 2020 to 31st May 2020. The participants were given an online pretested, validated questionnaire to ascertain the adverse effects while taking HCQ. Due to the nature of COVID-19 and restrictions on personal interview and examination, only online symptom questionnaire for adverse effects was given. 183 participants were involved in the study who were working as a health care professional in COVID-19. Out of these 9 participants were excluded based on the exclusion criteria. 73 adverse drug reaction were found in 56 participants. Most common and frequent side effects were headache, nausea, loose stools and dizziness. Almost 22 participants required some painkillers to treat the adverse effects. Data was entered in MS Excel and presented in the form of frequencies and percentages. Almost 32.18% reported adverse effects. So utmost care should be taken before using HCQ prophylactically in health care professionals working in COVID-19.

Keywords

Adverse Drug Reaction, Preexposure Prophylaxis, COVID 19, Hydroxychloroquine, Health Care Professionals

References

  1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The Lancet. 2000;356(9237):1255–1259. Available from: https://doi.org/10.1016/S0140-6736(00)02799-9
  3. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. British Journal of Clinical Pharmacology. 1998;45(3):301–308. Available from: https://doi.org/10.1046/j.1365-2125.1998.00667.x
  4. Dietz L, Horve PF, Coil DA, Fretz M, Eisen JA, Wymelenberg KVD. 2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission. 2019. Available from: https://doi.org/10.1128/mSystems.00245-20
  5. Lai CCC, Shih TPP, Ko WCC, Tang HJJ, Hsueh PRR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents. 2020;55(3):105924. Available from: https://doi.org/10.1016/j.ijantimicag.2020.105924
  11. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. 2020. Available from: https://doi.org/10.1136/bmj.m1849
  12. Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM. Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. 2020. Available from: https://pubmed.ncbi.nlm.nih.gov/32344449/
  13. García-Albéniz X, Amo JD, Polo R, Morales-Asencio JM, Hernán MA, . Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. European Journal of Epidemiology. 2022;37(8):789–796. Available from: https://pubmed.ncbi.nlm.nih.gov/35943669/
  14. Fallani E, Cevenini F, Lazzerini PE, Verdini A, Saponara S. Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance. The Journal of Clinical Pharmacology. 2022;62(5):646–655. Available from: https://pubmed.ncbi.nlm.nih.gov/34802170/
  15. Hempenius M, Bots SH, Groenwold RHH, Boer AD, Klungel OH, Gardarsdottir H. Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID19. Pharmacoepidemiology and Drug Safety. 2023;32(9):1001–1011. Available from: https://doi.org/10.1002/pds.5632

Copyright

© 2023 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 05 March 2024

Year: 2023, Volume: 22, Issue: 4


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.